Get complete information related to latest Resuscitator Tenders . from India at Classic Tenders. Search the best available tenders from Indian government tenders, domestic Resuscitator Tenders , private tenders, online tenders, tender invitation notice, business tender notices, online tenders and bidding Resuscitator Tenders.
Tender For srphc82281240-coronary drug eluting stents with (1) stent on cobalt chromium alloy or platinum chromium alloy. (2) stent with coating of polymer carrier for active drug ( sirolimus everolimus or zotarolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm and length of the stent should be 12mm to 48mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapidexchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) the long term efficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals. (10) the documents related to the efficacy and safety of the stent should be only for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of thestent to a major government institute. unit:no [ warranty period: 30 months after the date of delivery ] ]
Tender For empanelment for the supply of cathlab items on running contract basis under kasp and other schemes of this hospital - coronary stents, des,everolimus,fda/dcgi/ce approved platinum chromium platform,polyvinylidene fluride-hexafluropropyline pvdf-hfp polymer-stent lengths8,12,16,24,28,32. stent diameter 2.25*,2.50,2.75,3.00,3.50,4.00.struct thickness 81/86 microns.nominal pressure - 11 atm,rated burst pressure 16-18 atm, des,everolimus,fda/ approved platinum chromium platform,polyvinylidene fluoride-hexafluropropylene(pvdf-hfp)polymer, des,everolimus,fda/dcgi/ce/ approved platinum chromium platform,bioabsorbable polymer plga, everolimus eluting platinum chromium stent system, des, everolimus, l 605 cobalt chromium with hybrid cell design , strut thickness- 65microns, polymer- plga diameter- 2.25, 2.5, 2.75, 3.0, 3.5,4. length- 10,13,15,18,20,24, 28, 32,36,40, 42, 44, des, everolimus, cobalt chromium strut thickness - 63 microns . diameter- 2.25,2.5,2.75,3,3.5,4. length- 8,10,13,15,18,20,24,28,32,36,40,42,44. elutes 80% of drugs along with re plga polymer in the first 20 days, dcgi approved everolimus drug eluting 65 micron strut thickness with 3 micron plla&plga. a unique proprietory coating technology basedbiodegradable polymer stent with open cell designed and flexia finished technology based cobalt chromium l605 stent.a designed for optimal strength, flexibility ,trackablity ,side branch supported,bifurcation supported and high radial strength and optimal radiopacity and excellent vessel supported stent with revers alternative link design(ral) stent, with length from 8 mm to 52 mm and diameter from 2.25 mm to 4.50 mm, ce approved everolimus eluting coronary stent system struts/cells shows a wavy pattern and are not straight with outerradius of 0.1725mm. the cell angle is between 42 degree to 57 degree with respect to different diameter. the cells are connected by link (mid to mid pattern) with a radius of 0.2700mm. these values have been validated for lower stent profile, uniform expansion, side branch access, good trackability & strong radial support. components - drug: everolimus, stent platform: cobalt chromium l605 alloy, polymer: biodegradable, catheter: ptca rapid exchange semi-compliant stent delivery catheter. drug concentration: 1.2 microgram/mm2 of stent surface area. stent diameter(mm): 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00 & 4.50 & stent length (mm): 8, 13, 16, 20, 24, 28, 32, 36, 40, 43, 47 platinum-iridium radiopaque markers are precisely placed within the balloon cones for accurate stent positioning, also the difference between stent edge to marker is 0.5mm (atboth sides, proximal & distal) which prevents the dogboning during the angioplasty., ce approved sirolimus eluting coronary stent system struts/cells shows a wavy pattern and are not straight with outerradius of 0.1725mm. the cell angle is between 42 degree to 57 degree with respect to different diameter. the cells are connected by link (mid to mid pattern) with a radius of 0.2700mm. these values have been validated for lower stent profile, uniform expansion, side branch access, good trackability & strong radial support. components - drug: everolimus, stent platform: cobalt chromium l605 alloy, polymer: biodegradable, catheter: ptca rapid exchange semi-compliant stent delivery catheter. drug concentration: 1.2 microgram/mm2 of stent surface area. stent diameter(mm): 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00 & 4.50 & stent length (mm): 8, 13, 16, 20, 24, 28, 32, 36, 40, 43, 47 platinum-iridium radiopaque markers are precisely placed within the balloon cones for accurate stent positioning, also the difference between stent edge to marker is 0.5mm (atboth sides, proximal & distal) which prevents the dogboning during the angioplasty., only dcgi approved everolimus eluting coronary stent system struts/cells shows a wavy pattern and are not straight with outerradius of 0.1725mm. the cell angle is between 42 degree to 57 deg
Tender For corrigendum : supply of fire fighting equipment at ucspl d d - lt hand gloves , pvc clothing , resuscitator , water gel blanket , gas detectors , megaphone , safety torch , hand sirens , lt suits , ffe hoses , scba set
Tender For srphc82281240-coronary drug eluting stents with (1) stent on cobalt chromium alloy or platinum chromium alloy. (2) stent with coating of polymer carrier for active drug ( sirolimus, everolimus or zotarolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm and length of the stent should be 12mm to 48mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval shouldbe enclosed in the tender bid. (9) the long term efficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals. (10) the documents related to the efficacy and safety of the stent should be only for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent toa major government institute.[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]
Tender For srphc82281215-coronary drug eluting stents (1) with single wire design with cobalt alloy shell and platinum iridium core (2) stent with coating of biolinx polymer carrier for active drug zotarolimus shown to be effective in preventing neo-intimal hyperplasia (3) stent diameter should be from 2 mm to 5mm and length of the stent from 8 mm to 38 mm. (4) the strut should be round with thickness ranging from 81 to 91 microns (5) stent delivery system should be monorail (single operator exchange or rapidexchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) five years efficacy and safety of the stent in terms of target vessel revascularisation (tvr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals.(10) the documents pertaining to the efficacy and safety of the stent should be enclosed for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute. ]
Tender For supply of medicine and consumable etc - 2 fdc (p) dstb -cp (p) tab, 3 hp isoniazid plus rifapentine fdc (300mg/300mg) tablet, 3-0 mesh for lap ingunal hernia a)right side b)left side, 5-fluorouracil injection 500mg, 50mg/ml ampules, -hydroxyprogesterone injection 500 mg, aspirone suture 3-0 absorbale suture polyglecaprone 25 (filaproy), aspirone suture 3-0 absorbale suture polyglecaprone 25 (meril company), absorbable gelatin sponge, single unit, aceclofenac tablet 100 mg, aceclofence(100 mg)+ serratiopeptidase(10 mg)+paracetamol (325 mg) tab, acetazolamide tablet 250 mg, acetone 400 ml, acetylsalicylic acid tablet 150 mg, acetylsalicylic acid tablet 75 mg gastro-resistant (enteric coated/ delayed release), actinomycin injection 0.5 mg, acyclovir eye ointment 3% , 4.5 gm tube, acyclovir tablet 200 mg, acyclovir tablet 400 mg, acyclovir tablet 800 mg, acylovir eye oint 5%,5 gm, adenosine injection 3 mg/ ml, 1 ml ampoule, adrenaline injection 1 mg/ml, 1:1000, 1 ml amp, agfa cr film (dt2b)(1x100) 10"x12", agfa cr film (dt2b)(1x100) 11"x14", agfa cr film (dt2b)(1x100) 14"x17", agfa cr film (dt2b)(1x100) 8"x10", agomelatine tablet 25 mg, air mattress, airway set size 2, ( single unit), airway set size 3, ( single unit), airway set size 4, ( single unit), airway set size 5, ( single unit), akt3 tablet, akt4 tablet, albendazole chewable tablet 400 mg, albendazole oral suspension 200 mg/5 ml,10 ml bottle, alfacalcidol soft gelatin capsule 0.25 mcg, alkalizer mb6 500ml (potassium citrate magnisum citrate syrup & vit b6), allopurinol tablet 100 mg, alprazolam tablet 0.25 mg, alprazolam tablet 0.5 mg, aluminium hydroxide 240 mg + magnesium hydroxide 100mg+ simethicone 25 mg + magnesium carbonate 60 mg chewable tablet, ambu bag adult, it should be double layered resuscitator within built pressure limiting system that prevents airways pressure from exceeding 7 k pa ( 70 cm h2o without loss of valume. it should be supplied with reusable transparent breathing face mask , it should have tidal volume max 1300 ml it should be usfda and iso/ce certified. (single unit), ambu bag ped, it should be double layered resuscitator within built pressure limiting system that prevents airways pressure from exceeding 4 k pa ( 40 cm h2o without loss of valume. it should be supplied with reusable transparent breathing face mask , it should have tidal volume max 300 ml it should be usfda and iso/ce certified. (single unit), amikacin injection 250mg/ ml, 2 ml vial, amikacin injection 50 mg/ ml, 2 ml vial, amino acid iv infusion minimum 10 essential amino acids, 200ml bottle, aminophylline injection 25 mg/ ml, 10 ml ampoule, amiodarone tablet 100 mg, amisulpiride 100 mg tab., amisulpride tablet 50 mg, amitriptyline tablet 10 mg, amitriptyline tablet 25 mg, amlodipine tablet 10 mg, amlodipine tablet 5 mg, amorolfine cream (0.25%), amoxicillin + clavulanic acid injection 1.2 gm , 10 ml vial with diluents, amoxicillin + clavulanic acid injection 250 mg +50 mg, vial with diluents, amoxicillin + pottasium clavulanate dispersible tablet 200 mg +28.5 mg, amoxicillin + pottasium clavulanate tablet 500 mg + 125 mg, amoxicillin capsule 250 mg, amoxicillin capsule 500 mg, amoxicillin oral suspension 125 mg/5 ml, 60 ml bottle, amphotericin b powder for injection 50 mg and vial has sodium deoxychlolate or liposomal complex, amphotericin b powder for injection 50 mg liposomal complex,vial injection powder 50mg/ml, 10ml vial, ampicillin sodium injection 500mg 2 ml vial with diluent, anterior chamber kellmann multi flex 4 point fixation type optical diameter 6mm,overall length 12.5 mm, dioptric range 10d to 30 d, anti diptheria serum, anti hemophillic factor ix vial injection size 500 iu, anti hemophillic factor ix. anti hemophillic factor ix should be : vial size atleast 500 iu, calculation will be made per unit dose, 600 iu vial, anti hemophillic factor vii injection 1mg,vial/ampoule, anti hemophillic factor vii injection 2mg,vial/ampole, anti hemophillic factor viii inhi
Tender For srphc82281210-coronary drug eluting stents (1) single wire technology on cobalt based alloy platform (2) stent with coating of biolinx polymer carrier for active drug zotarolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.25 mm to 4 mm and length of the stent from 12mm to 38 mm. (4) the strut thickness should be 81 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) five years long term efficacy and safety of the stent in terms of target vesselrevascularisation (tvr) and in-situ thrombosis (ist) should be documented / published inpeer reviewed scientific journals.(10) the documents pertaining to the efficacy and safety of the stent should be enclosed for the brand that is offered in the tender bid (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute.[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]
Tender For srphc82281275-des-abbreviated dapt long -coronary drug eluting stents with (1) platinum chromium alloy (2) coating of bioabsorbable polymer carrier for activedrug everolimus shown to be effective in preventing neo-intimal hyperplasia) (3) stent diameter should be from 2.5mm to 4mm. the length of the stent should be from 12mm to 48 mm. (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) the long term efficacy and safety of the stent, the rates of in-stent restenosis (isr) and in-situ thrombosis (ist) should be documented / published in peer reviewed scientific journals. (10) safety of abbreviated (three month) dual antiplatelet therapy for high bleeding risk patients should be documented in peer reviewed journals. (11) the manufacturer/supplier should submit proof of supply of the stent to a major government institute. bis standards for the drug eluting stent are not available. (reference:bis catalogue ).[quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitted: max 8 lacs ] ]